Stock INO INOVIO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
9.68 USD -5.10% Intraday chart for Inovio Pharmaceuticals, Inc. -12.24% +58.17%
Apr. 16 Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell MT
Apr. 16 Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants MT

Business Summary

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Number of employees: 122

Sales per Business

USD in Million2022Weight2023Weight Delta
DNA Medicines
100.0 %
10 100.0 % 1 100.0 % -91.89%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
10 100.0 % 1 100.0 % -91.89%

Managers

Managers TitleAgeSince
Jacqueline Shea CEO
 Chief Executive Officer 58 19-03-24
Peter Kies DFI
 Director of Finance/CFO 60 02-05-31
Stephen Kemmerrer CTO
 Chief Tech/Sci/R&D Officer - 07-01-31
Jeffrey Skolnik CTO
 Chief Tech/Sci/R&D Officer - 16-10-11
Michael Sumner CTO
 Chief Tech/Sci/R&D Officer 59 22-06-26
Laurent Humeau CTO
 Chief Tech/Sci/R&D Officer 57 14-02-17
Thomas Hong IRC
 Investor Relations Contact - -
Cheryl Elder LAW
 General Counsel - -
Shawn D. Bridy PRN
 Corporate Officer/Principal - 18-05-23
Maggie Campbell AUD
 Comptroller/Controller/Auditor - 06-02-28

Members of the board

Members of the board TitleAgeSince
Simon Benito CHM
 Chairman 79 03-11-30
Lota Zoth BRD
 Director/Board Member 64 17-12-31
Jay Shepard BRD
 Director/Board Member 66 20-01-14
Wendy Yarno BRD
 Director/Board Member 68 17-12-05
David Weiner FOU
 Founder 67 83-06-28
Jacqueline Shea CEO
 Chief Executive Officer 58 19-03-24
Roger Dansey BRD
 Director/Board Member 68 21-05-12
Ann Miller BRD
 Director/Board Member 66 19-03-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,091 0 1,082 ( 99.18 %) 98.51 %
Stock B 1 25,329,333 24,953,826 ( 98.52 %) 0

Shareholders

NameEquities%Valuation
Vanguard Global Advisers LLC
7.048 %
1,647,166 7.048 % 23 M $
Renaissance Technologies LLC
2.602 %
608,112 2.602 % 8 M $
BlackRock Institutional Trust Co. NA
1.402 %
327,712 1.402 % 5 M $
GSA Capital Partners LLP
1.354 %
316,376 1.354 % 4 M $
Geode Capital Management LLC
1.024 %
239,286 1.024 % 3 M $
D.E. Shaw & Co., Inc.
0.9632 %
225,096 0.9632 % 3 M $
J. Kim
0.8365 %
195,499 0.8365 % 3 M $
Jacobs Levy Equity Management, Inc.
0.4101 %
95,831 0.4101 % 1 M $
David Weiner
0.3438 %
80,343 0.3438 % 1 M $
Acadian Asset Management LLC
0.3170 %
74,083 0.3170 % 1 M $

Company contact information

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike Suite 110

19462-1111, Plymouth Meeting

+267 440 4200

http://www.inovio.com
address Inovio Pharmaceuticals, Inc.(INO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Inovio Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
9.68 USD
Average target price
19.25 USD
Spread / Average Target
+98.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INOVIO PHARMACEUTICALS, INC. Stock Inovio Pharmaceuticals, Inc.
+58.17% 251M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.52B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 39.9B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 38.83B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.05B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 23.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.65B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.53B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INO Stock
  4. Company Inovio Pharmaceuticals, Inc.